News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche Holding AG (RHHBF.PK)'s (JOBS) MabThera Cuts Arthritis Joint Damage


6/11/2009 7:44:49 AM

Bookmark and Share

Reuters -- Data showed Roche Holding AG's MabThera cancer drug reduced the progression of joint damage when used as a first line treatment for rheumatoid arthritis (RA), the Swiss group said on Thursday. Results of the so-called IMAGE study, presented at a European League Against Rheumatism meeting, showed a course of two infusions of MabThera given every 24 weeks can significantly slow damage after one year of treatment.


Read at Reuters
Read at Wall Street Journal
Read at HAYS Pharma

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES